Latanoprost
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00654 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 34 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary hereditary glaucoma | KG + DL |
| 2 | visceral calciphylaxis | KG + DL |
| 3 | hypotrichosis simplex of the scalp | KG + DL |
| 4 | arterial thoracic outlet syndrome | KG + DL |
| 5 | venous thoracic outlet syndrome | KG + DL |
| 6 | neurogenic thoracic outlet syndrome | KG + DL |
| 7 | congenital hypotrichosis milia | KG + DL |
| 8 | angiodysplasia of stomach | KG + DL |
| 9 | blue toe syndrome | KG + DL |
| 10 | lymphangiectasis | KG + DL |
| 11 | hemangioendothelioma | KG + DL |
| 12 | vascular disease | KG + DL |
| 13 | atheroembolism of kidney | KG + DL |
| 14 | idiopathic spontaneous coronary artery dissection | KG + DL |
| 15 | diffuse alopecia areata | KG + DL |
| 16 | arterial dissection-lentiginosis syndrome | KG + DL |
| 17 | alopecia | KG + DL |
| 18 | congestive heart failure | KG + DL |
| 19 | acute pulmonary heart disease | KG + DL |
| 20 | hepatic porphyria | KG + DL |
| 21 | primitive portal vein thrombosis | KG + DL |
| 22 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 23 | hepatoportal sclerosis | KG + DL |
| 24 | idiopathic copper-associated cirrhosis | KG + DL |
| 25 | hepatopulmonary syndrome | KG + DL |
| 26 | respiratory failure | KG + DL |
| 27 | glaucoma 1, open angle | KG + DL |
| 28 | open angle glaucoma | KG + DL |
| 29 | subarachnoid hemorrhage (disease) | KG + DL |
| 30 | Moyomoya angiopathy | KG + DL |
| 31 | conjunctival vascular disease | KG + DL |
| 32 | heart failure | KG + DL |
| 33 | idiopathic macular telangiectasia | KG + DL |
| 34 | vasoproliferative tumor of retina | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.